New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics and Alligator Bioscience at Prominent Industry Conferences
Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events
pharmaceutical-investing Actinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform Technology
pharmaceutical-investing Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study of EG-1962
Organovo Division Samsara Sciences Announces Multi-Year Supply Agreement With Lonza Bioscience Solutions
